Photodynamic therapy as treatment of chronic idiopathic central serous chorioretinopathy

Abstract

Our data suggest that PDT leads to resolution of serous detachments and visual improvement in patients with chronic ICSC. Further follow-up would be prudent to assess the long-term outcomes and safety in this patient population.

Photodynamic therapy for central serous chorioretinopathy

“…In Chan et al's study, one juxtafoveal CNV developed 3 months post standard PDT treatment. 23,25,26,30,33,34,36,37,41,46 Variation in verterporfin dose: The variation in verteporin dose PDT group had the best results in terms of resolution of SRF and improvement of BCVA post PDT treatment. In the half-dose verterporfin group, complete resolution of SRF was seen in three out of seven studies (42.9%) at the end of each study's follow-up period.…”

“…Mean laser spot size ranged between 1300 and 6800mm. 15,[17][18][19][20][21][22][23][24][25][26][27][29][30][31][33][34][35][36][37]39,[41][42][43][44]46,47 Thirteen studies (n ¼ 13, 54.2%) used a mean spot size o4500 mm. The spot size was not mentioned in seven studies.…”

“…A similar pattern was noticed in Silva et al at 48 months with a reduction in CMT from 316 ± 114 to 169.7 ± 41.1 mm. 15,[17][18][19][20][21][22][23][24][25][26][27][29][30][31][33][34][35][36][37]46,47 Choroidal thickness on OCT Three studies assessed the choroidal thickness before and after PDT treatment (See Table 5 42 demonstrated that choroidal thickness in the area treated with PDT initially increased after treatment, then decreased. Pyrds and Larsen showed that choroidal thickness in the area where PDT was applied decreased from 407 mm (mean; 95% CI 356-458 mm) to 349 mm (mean; CI 95% 300-399 mm; Po0.0001), and subfoveal choroidal thickness was reduced from 421 mm (mean; CI 95% 352-489 mm) to 346 mm (mean; CI 95% 278-414 mm; P ¼ 0.0001).…”

Long-term chorioretinal changes after photodynamic therapy for chronic central serous chorioretinopathy

“…Several studies have shown favorable results with PDT in treating chronic CSC [4][5][6][7][8][9][10][11][12][13][14][15][16]. Our report is the first one to describe the efficacy, the safety, and the chorioretinal changes 5 or more years after standard PDT for chronic CSC.…”

“…The high rate of spontaneous resolution provides that conservative management can be adopted as first-line treatment in most cases [3]. Photodynamic therapy (PDT) with verteporfin has shown good results, both anatomic and functional, in treating chronic CSC, with either standard or reduced fluence (600 mW/cm 2 , 300 mW/cm 2 respectively) and with either standard or half dose (6 mg/m 2 or 3 mg/m 2 respectively) [4][5][6][7][8][9][10][11][12][13][14][15][16]. However, it has been reported that PDT can be associated with potential side-effects, such as RPE atrophy, neuroretinal thickness (NRT) thinning, development of choroidal neovascularization (CNV), and reduction in macular function [15][16][17][18][19].…”